| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 14.783 | 138.506 | 691.150 | 1.429.848 | 403.525 | 891.549 | 597.355 |
| Total Income - EUR | - | - | - | 14.783 | 138.507 | 691.218 | 1.429.803 | 409.599 | 899.092 | 614.586 |
| Total Expenses - EUR | - | - | - | 11.102 | 87.323 | 424.650 | 957.396 | 368.854 | 690.027 | 382.051 |
| Gross Profit/Loss - EUR | - | - | - | 3.681 | 51.183 | 266.569 | 472.407 | 40.746 | 209.065 | 232.535 |
| Net Profit/Loss - EUR | - | - | - | 3.238 | 48.144 | 259.960 | 409.894 | 33.193 | 182.069 | 192.305 |
| Employees | - | - | - | 0 | 2 | 4 | 5 | 4 | 4 | 2 |
Check the financial reports for the company - Pharmamed Consulting & Investment S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 12.004 | 57.971 | 64.097 | 46.627 | 48.006 | 26.921 |
| Current Assets | - | - | - | 6.098 | 58.873 | 346.897 | 636.231 | 293.413 | 529.296 | 551.399 |
| Inventories | - | - | - | 563 | 5.724 | 60.329 | 105.478 | 209.563 | 116.209 | 109.685 |
| Receivables | - | - | - | 946 | 42.346 | 279.222 | 246.020 | 85.164 | 427.725 | 462.433 |
| Cash | - | - | - | 4.589 | 10.802 | 7.346 | 284.733 | -1.315 | -14.638 | -20.719 |
| Shareholders Funds | - | - | - | 3.281 | 51.361 | 260.010 | 409.943 | 33.242 | 182.724 | 192.353 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 2.817 | 19.515 | 144.858 | 290.385 | 306.798 | 394.578 | 385.967 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7499 - 7499" | |||||||||
| CAEN Financial Year |
7490
|
|||||||||
Comments - Pharmamed Consulting & Investment S.r.l.